FACCHETTI, FLORIANA
 Distribuzione geografica
Continente #
EU - Europa 4.250
NA - Nord America 2.611
AS - Asia 1.319
SA - Sud America 45
AF - Africa 40
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.296
Nazione #
US - Stati Uniti d'America 2.517
GB - Regno Unito 1.879
CN - Cina 777
DE - Germania 648
IT - Italia 525
SE - Svezia 378
FR - Francia 211
IN - India 115
UA - Ucraina 108
IE - Irlanda 98
RU - Federazione Russa 89
KR - Corea 84
TR - Turchia 84
CA - Canada 83
HK - Hong Kong 64
JP - Giappone 64
DK - Danimarca 58
EU - Europa 54
FI - Finlandia 52
PL - Polonia 41
NL - Olanda 40
GR - Grecia 31
BE - Belgio 29
AU - Australia 27
CO - Colombia 24
TW - Taiwan 24
SG - Singapore 22
ES - Italia 19
VN - Vietnam 19
ID - Indonesia 16
CH - Svizzera 12
MX - Messico 11
EG - Egitto 10
SL - Sierra Leone 10
CY - Cipro 9
AT - Austria 8
BR - Brasile 8
IR - Iran 8
IQ - Iraq 6
MA - Marocco 6
AR - Argentina 5
MM - Myanmar 5
PT - Portogallo 5
DZ - Algeria 4
GH - Ghana 4
PE - Perù 4
PH - Filippine 4
TH - Thailandia 4
IL - Israele 3
LT - Lituania 3
BD - Bangladesh 2
BG - Bulgaria 2
CL - Cile 2
CZ - Repubblica Ceca 2
HU - Ungheria 2
KE - Kenya 2
MY - Malesia 2
NZ - Nuova Zelanda 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UZ - Uzbekistan 2
AL - Albania 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
ET - Etiopia 1
KW - Kuwait 1
MD - Moldavia 1
PK - Pakistan 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 8.348
Città #
Southend 1.744
Chandler 354
Milan 198
Seattle 153
Beijing 147
Wilmington 132
Ann Arbor 129
Princeton 126
Fairfield 122
Ashburn 116
Dublin 96
Frankfurt am Main 94
Dearborn 84
Woodbridge 82
Jacksonville 77
Mountain View 77
Nanjing 70
Houston 69
Redmond 51
Des Moines 48
Redwood City 48
Toronto 47
Shanghai 46
Bengaluru 41
Hong Kong 40
Boardman 39
Shenyang 34
Cambridge 32
Serra 32
Hebei 31
Scranton 31
Andover 30
Jinan 30
Kiez 30
Sakarya 29
Warsaw 29
Hanover 27
Brussels 26
Somerville 26
Hangzhou 25
Grafing 24
Phoenix 24
Bogotá 23
Roxbury 23
Guangzhou 22
Nürnberg 22
Sunnyvale 21
Changsha 20
Berlin 19
Zhengzhou 18
New York 17
Saint Petersburg 17
Tianjin 16
Tokyo 16
Munich 15
Bari 14
Athens 13
Helsinki 13
Nanchang 13
Chongqing 12
Kunming 12
Taipei 12
San Diego 11
Auburn Hills 10
Central District 10
Chengdu 10
Fremont 10
Bitonto 9
Hefei 9
London 9
Seoul 9
Boise 8
Brescia 8
Dong Ket 8
Los Angeles 8
Medford 8
Ottawa 8
Rome 8
Camden 7
Cinisello Balsamo 7
Eitensheim 7
Fairfax 7
Gorla Maggiore 7
Krakow 7
Kwai Chung 7
Montreal 7
Ningbo 7
Piscataway 7
Taiyuan 7
Cairo 6
Gussago 6
Haikou 6
Jakarta 6
Lanzhou 6
Legnano 6
Palaiseau 6
Silver Spring 6
Singapore 6
Birmingham 5
Bologna 5
Totale 5.312
Nome #
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential 650
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 414
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors 395
Unique expression and
localization of aquaporin- 4 and aquaporin-9 in murine and human neural stem
cells and in their glial progeny 360
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 335
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma 313
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice : high efficacy and favorable safety profile over 3 years of treatment 254
Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs 246
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients 205
Cancer stem cells and therapeutic perspectives 176
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B 172
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 172
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 168
BRAF V599E mutation occurs in Spitz and Reed nevi 166
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 152
Allelic inhibition of displacement activity : a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 149
CARATTERIZZAZIONE MOLECOLARE DELLA FARMACO-RESISTENZA IN PAZIENTI NAIVE CON EPATITE CRONICA B TRATTATI CON ENTECAVIR 148
Knockdown of AQP1 in HMEC-1 cells and WM115 cells changes the organisation of the cytoskeleton 146
New perspectives in the treatment of melanoma : anti-angiogenic and anti-lymphoangiogenic strategies 144
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 143
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 141
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 139
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 137
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 137
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 137
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 134
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 134
Lamivudine prophylaxis of hepatitis B reactivation in anti-HBC seroposivive patients undergoing chemotherapy for onco-hematological diseases 132
Identification of stem cell like population in human melanoma 128
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 127
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B 125
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 122
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 121
Failure of adefovir 20 mg to improve suboptimal response in lamivudine resistant hepatitis B patients treated with adefovir 10 mg and lamivudine 119
CD133 postive cellular population in human melanoma 115
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection 114
Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance 110
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 109
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients 107
Effect of a caloric restriction regimen on the angiogenic capacity of aorta and on the expression of endothelin-1 during ageing 100
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy 100
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 94
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients 93
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 92
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal 90
Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT 86
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy 86
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients 85
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B 81
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection 79
CD133 positive cellular population in human melanoma 76
Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B 73
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib : The ALICE-1 study 65
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide 65
TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues 53
Reticulohistiocytosis 35
Erheim-Chester disease 35
Introduction to histiocytic and dendritic cell neoplasms 34
Indeterminate cell histiocytosis/indeterminate dendritic cell tumour 28
Langerhans cell histiocytosis 27
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension 11
Defect of regulatory T cells in patients with Omenn syndrome 10
Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients 1
Totale 8.795
Categoria #
all - tutte 18.566
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.566


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019309 0 0 0 0 0 0 0 0 0 133 105 71
2019/20201.269 165 98 58 148 68 135 100 92 181 124 60 40
2020/20211.016 49 67 59 45 74 63 72 51 152 83 155 146
2021/20221.004 74 47 51 62 67 60 79 74 89 126 64 211
2022/20231.157 135 148 106 114 114 197 35 86 128 18 49 27
2023/2024649 37 62 44 37 184 45 83 65 49 43 0 0
Totale 8.795